Pay in 4 interest-free payments of $6.67 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Alterity Therapeutics received FDA Fast Track designation in 2025 for ATH434, a small molecule targeting iron dysregulation in MSA, a mechanism distinct from alpha-synuclein aggregation approaches
Increased kynurenine plasma concentrations and kynurenine-tryptophan ratio in mild-to-moderate chronic obstructive pulmonary disease patients
By using microdoses, patients may achieve the benefits of this cutting-edge peptide while minimizing potential side effects
Weve lowered our GLP-1 pricing
Understanding GLP-1 Side Effects: Beyond the Common Digestive Issues These medications are instrumental in managing blood sugar for individuals with type 2 diabetes and also support weight loss, regardless of diabetes status
US$ 22.73
US$ 23.62
US$ 26.20
US$ 29.01
